Home > Oncology > ASCO 2020 > Genitourinary Cancer > First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

TheraP is the first (non-blinded) trial comparing Lu-PSMA to an active therapy with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel. Results demonstrated that Lu-PSMA has high activity and relatively low toxicity, consistent with the results of prior single-centre phase 2 data. Lu-PSMA appears to represent a favourable treatment option compared with cabazitaxel in a selected population with high PSMA expression.

In the last 2 decades, several life prolonging therapies have been approved for the treatment of mCRPC, including docetaxel, cabazitaxel, abiraterone, enzalutamide, sipuleucel-T, and 223Ra. Recently, 177Lutetium-PSMA-617 (Lu-PSMA) has been developed. Lu-PSMA is a radiolabelled small molecule which binds with high affinity to prostate-specific membrane antigen (PSMA), a cell surface glycoprotein overexpressed in metastatic prostate cancer. This enables delivery of high doses of radiation wi...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on